NCT06304350View on ClinicalTrials.gov

Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 17, 2024

Primary Completion Date

February 25, 2026

Study Completion Date

December 31, 2026

Conditions
Esophageal Cancer
Interventions
DRUG

Combination of pembrolizumab and platinum containing dual drugs

After 2 courses of treatment with a combination of pembrolizumab and platinum containing dual drugs (albumin paclitaxel+carboplatin), surgery was performed and pembrolizumab immunomaintenance therapy continued after surgery

Trial Locations (1)

200080

RECRUITING

Shanghai General Hospital, Shanghai

All Listed Sponsors
lead

Tongji University

OTHER